AngioDynamics (ANGO) financial statements
AngioDynamics reported revenue of $320M in fiscal 2026, up 1.9% a year over 9 years.
Net income was -$37M and the operating margin -12.5%, against -4.1% in 2017.
Free cash flow was $508,000.
The diluted share count rose 13% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from AngioDynamics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $270M | $262M | $271M | $264M | $291M | $316M | $339M | $304M | $292M | $320M |
| Cost of revenue | $126M | $118M | $115M | $114M | $134M | $150M | $165M | $149M | $135M | $145M |
| Gross profit | $144M | $144M | $156M | $150M | $157M | $166M | $174M | $155M | $158M | $175M |
| Research and development | $24M | $24M | $28M | $30M | $36M | $31M | $30M | $32M | $26M | $29M |
| Selling, general and admin | $106M | $104M | $112M | $117M | $117M | $134M | $144M | $144M | $145M | $157M |
| Operating income | -$11M | -$14M | -$9M | -$167M | -$35M | -$28M | -$51M | -$192M | -$40M | -$40M |
| Interest expense | $3M | $3M | $5M | $907,000 | $861,000 | $688,000 | $3M | -$2M | — | — |
| Pre-tax income | -$14M | -$17M | -$15M | -$168M | -$36M | -$30M | -$54M | -$192M | -$34M | -$36M |
| Income tax | -$7M | -$11M | -$4M | -$1M | -$5M | -$3M | -$2M | -$7M | -$39,000 | $442,000 |
| Net income | $5M | $16M | $61M | -$167M | -$32M | -$27M | -$52M | -$184M | -$34M | -$37M |
| EPS (diluted) | $0.14 | $0.44 | $1.64 | -$4.39 | -$0.82 | -$0.68 | -$1.33 | -$4.59 | -$0.83 | -$0.88 |
| Diluted shares | 37M | 37M | 37M | 38M | 38M | 39M | 39M | 40M | 41M | 42M |
| Gross margin | 53.4% | 55.0% | 57.6% | 56.9% | 53.9% | 52.4% | 51.4% | 50.9% | 53.9% | 54.6% |
| Operating margin | -4.1% | -5.4% | -3.5% | -63.3% | -12.1% | -9.0% | -15.1% | -63.3% | -13.7% | -12.5% |
| Net margin | 1.9% | 6.2% | 22.7% | -63.1% | -10.8% | -8.4% | -15.5% | -60.7% | -11.6% | -11.5% |
Balance sheet
Fiscal years, from AngioDynamics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $49M | $75M | $228M | $54M | $48M | $29M | $45M | $76M | $56M | $54M |
| Receivables | $45M | $39M | $44M | $31M | $35M | $52M | $53M | $44M | $43M | $48M |
| Inventory | $55M | $39M | $40M | $60M | $49M | $51M | $55M | $61M | $62M | $52M |
| Total current assets | $154M | $168M | $315M | $153M | $141M | $143M | $164M | $193M | $168M | $163M |
| Property, plant and equipment | $45M | $26M | $24M | $28M | $37M | $45M | $44M | $36M | $32M | $27M |
| Goodwill | $361M | $286M | $348M | $201M | $201M | $201M | $159M | $0 | — | — |
| Total assets | $708M | $705M | $836M | $594M | $561M | $553M | $533M | $318M | $280M | $267M |
| Total current liabilities | $72M | $57M | $73M | $51M | $58M | $74M | $84M | $91M | $76M | $75M |
| Long-term debt | $91M | $87M | $124M | — | — | — | — | — | — | — |
| Total liabilities | $193M | $163M | $222M | $139M | $122M | $128M | $154M | $112M | $97M | $96M |
| Shareholders' equity | $515M | $543M | $615M | $455M | $439M | $424M | $378M | $206M | $183M | $171M |
| Net debt | $49M | $18M | -$96M | -$54M | -$48M | -$29M | -$45M | -$76M | -$56M | -$54M |
Cash flow
Fiscal years, from AngioDynamics's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $56M | $41M | $37M | -$15M | $24M | -$7M | $78,000 | -$28M | -$10M | $3M |
| Capital spending | $3M | $2M | $3M | $7M | $5M | $4M | $4M | $3M | $4M | $3M |
| Free cash flow | $53M | $39M | $34M | -$22M | $19M | -$11M | -$4M | -$31M | -$15M | $508,000 |
| Stock-based compensation | $6M | $8M | $9M | $8M | $9M | $11M | $11M | $11M | $10M | $14M |
| Share buybacks (net) | -$14M | $0 | $0 | — | — | — | $0 | $0 | -$2M | $0 |
| Net borrowing | -$24M | -$5M | -$15M | -$132M | -$20M | $0 | -$45M | -$50M | $0 | $0 |
| Free cash flow margin | 19.6% | 14.9% | 12.7% | -8.2% | 6.5% | -3.6% | -1.1% | -10.1% | -5.0% | 0.2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ANGO.
Open ANGO in InvestinglyQuestions
What was AngioDynamics's revenue in 2026?
$320M in fiscal 2026, from its 10-K filing.
How much free cash flow does AngioDynamics generate?
$508,000 in fiscal 2026 (operating cash flow minus capital spending).
From AngioDynamics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.